Translating genetic risk of Alzheimer’s disease into mechanistic insight and drug targets
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
To provide better prevention and treatment, we need to understand the environmental and genetic risks of Alzheimer’s disease (AD). However, the definition of AD has been confounded with dementia in many studies. Thus, overinterpretation of genetic findings with regard to mechanisms and drug targets may explain, in part, controversies in the field. Here, we analyze the different forms of genetic risk of AD and how these can be used to model disease. We stress the importance of studying gene variants in the right cell types and in the right pathological context. The lack of mechanistic understanding of genetic variation has become the major bottleneck in the search for new drug targets for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Jansen, I. E., Savage, J. E., Watanabe, K., Bryois, J., Williams, D. M., Steinberg, S., Sealock, J., Karlsson, I. K., Hägg, S., Athanasiu, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0311-9 · Cited by 2,277
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · cited 2×
“The rare R47H and more common R62H variants of TREM2 ( 15 ) alter its stability, affect phagocytic capacity and impair TREM2 affinity for APOE, clusterin (ApoJ), low-density lipoproteins (LDL) and Aβ ( 33 ).”
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Role of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798 · cited 1×
“Given the high heritability of AD (6, 7), studying genetic risk seems a more fruitful way forward to identify molecular mechanisms of disease.”
BackgroundAPOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281
Cited by
Biomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Neuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581
“Besides fully penetrant mutations, some risk variants encode for genes that enrichened in microglia [see this recent review for a comprehensive description on genetic risk in AD (Sierksma et al., 2020)].”
BackgroundAstrocyte-neuron metabolic cooperation shapes brain activity
Bonvento, G., & Bolaños, J. P. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.07.006 · Cited by 580
Solving neurodegeneration: common mechanisms and strategies for new treatments
Wareham, L. K., Liddelow, S. A., Temple, S., Benowitz, L. I., Di Polo, A., Wellington, C., Goldberg, J. L., He, Z., Duan, X., Bu, G., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00524-0 · Cited by 324
Lopes, K. D. P., Snijders, G. J. L., Humphrey, J., Allan, A., Sneeboer, M. A. M., Navarro, E., Schilder, B. M., Vialle, R. A., Parks, M., Missall, R., et al. (2022) · Nature Genetics · doi:10.1038/s41588-021-00976-y · Cited by 273
Periodontal microorganisms and Alzheimer disease – A causative relationship?
Jungbauer, G., Stähli, A., Zhu, X., Auber Alberi, L., Sculean, A., & Eick, S. (2022) · Periodontology 2000 · doi:10.1111/prd.12429 · Cited by 174
A multi-pronged human microglia response to Alzheimer’s disease Aβ pathology
Mancuso, R., Fattorelli, N., Martinez-Muriana, A., Davis, E., Wolfs, L., Van Den Daele, J., Geric, I., Preman, P., Serneels, L., Poovathingal, S., et al. (2022) · doi:10.1101/2022.07.07.499139 · Cited by 169
“Microglia are a central part of the cellular response in Alzheimer’s disease (AD) pathogenesis 1,2 , in particular in the early response to amyloid-β (Aβ) pathology 3–6 .”
BackgroundBaligács, N., Albertini, G., Borrie, S. C., Serneels, L., Pridans, C., Balusu, S., & De Strooper, B. (2024) · Nature Communications · doi:10.1038/s41467-024-54779-w · Cited by 123
“This genetic risk for late-onset AD is largely associated with microglia, indicating a crucial role of these cells in modulating the disease 7,8 .”
Artificial intelligence for drug discovery and development in Alzheimer's disease
Qiu, Y., & Cheng, F. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102776 · Cited by 83
Cheng, F., Wang, F., Tang, J., Zhou, Y., Fu, Z., Zhang, P., Haines, J. L., Leverenz, J. B., Gan, L., Hu, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101379 · Cited by 63
Alzheimer disease and the periodontal patient: New insights, connections, and therapies
Ryder, M. I., & Xenoudi, P. (2021) · Periodontology 2000 · doi:10.1111/prd.12389 · Cited by 55
Wang, Y.-Y., Ge, Y.-J., Tan, C.-C., Cao, X.-P., Tan, L., & Xu, W. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201606 · Cited by 49
microRNA-132 regulates gene expression programs involved in microglial homeostasis
Walgrave, H., Penning, A., Tosoni, G., Snoeck, S., Davie, K., Davis, E., Wolfs, L., Sierksma, A., Mars, M., Bu, T., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106829 · Cited by 41
Self-citationXue, F., Tian, J., Yu, C., Du, H., & Guo, L. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105272 · Cited by 32
Illouz, T., Nicola, R., Ben-Shushan, L., Madar, R., Biragyn, A., & Okun, E. (2021) · Communications Biology · doi:10.1038/s42003-021-01851-6 · Cited by 21
Li, H., Initiative, F. T. A. D. N., Liu, H., Lutz, M. W., & Luo, S. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-220680 · Cited by 17
“Also, the single nucleotide polymorphism (SNP)-based heritability can account for 24–53% among the genetic risk factors [7].”
Graham, A. C., Bellou, E., Harwood, J. C., Yaman, U., Celikag, M., Magusali, N., Rambarack, N., Botia, J. A., Frigerio, C. S., Hardy, J., et al. (2023) · doi:10.1101/2023.03.30.23287975 · Cited by 4
Self-citationPLCG2 signaling and genetic resilience in Alzheimer’s disease
Tsai, A. P., Martin, A. K., Mi, A., Yeh, A. E., Ramirez Lopez, E., & Wyss-Coray, T. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00935-3
Metadata
- Authors
- Sierksma, A., Escott-Price, V., & De Strooper, B.
- Venue
- Science
- Published
- 2020-10-02
- Volume
- 370
- Issue
- 6512
- Pages
- 61-66
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3090238527
- Cited by
- 146
- References
- 43
- FWCI
- 9.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.